Download presentation
Presentation is loading. Please wait.
1
Gynaecological Cancers
Malcolm Padwick MD FRCOG
2
Cervical Cancer
3
Cervical Cancer 1992 national targets set for year 2000
1. Reduce mortality by 20% 2. Achieve 80% smear uptake 1991 targets had already been achieved Mortality rate had been falling since 1950 at a rate of 1 -2 % per annum Now 2.3 per
4
At risk groups Young (immature TZ)
Early age of first sexual intercourse Multiple partners Smoking Type of contraception Screening history
5
Screening intervals (2004)
Age Group (years) Frequency of Screening 25 First invitation 3 yearly 5 yearly 65+ No screen since age 50 yrs or recent abnormal smear
6
HPV HPV subtyping will become available
Concentrate screening on genuinely at risk women Allow an increase in the screening interval Avoid unnecessary intervention
7
Referral to Colposcopy
3 inadequate smears 2 mildly dyskariotic / borderline smears First moderately or severely dyskariotic smear Glandular abnormalities Suspicion of malignancy
8
Colposcopy visit Information sheets with appointment
Separate clinic waiting area Changing and washing facilities Separate consultation area Comply with NHSCSP appointment waiting times Comply with NHSCSP waiting times for results
9
Scale of problem Therefore a follow-up policy change introduced (NHS)
Watford referrals 1995 228 new patients Watford referrals 2003 618 new patients Therefore a follow-up policy change introduced (NHS)
10
Colposcopy Assess Biopsy and act on results when available
See and treat
14
After effects 3 weeks of diminishing blood stained discharge
Risk of secondary infection at 1 week Next period often heavy and painful Overall post operative pain is minimal >98% have a clear or better smear result at 6 months
15
Cervical cancer From colposcopy General clinic with abnormal bleeding
Acute admission with symptoms of advanced disease
16
Staging EUA and cystoscopy Pelvic MRI Abdominal and chest CT
19
Treatment Surgery Cone biopsy Radical trachylectomy
Radical hysterectomy Neoadjuvant chemotherapy combined with radical surgery exenteration
20
Treatment Chemo-radiation as a primary treatment
Radiotherapy as post operative treatment for poor prognostic disease Chemotherapy or radiotherapy for palliation
21
consequences Surgery Acute complications Fistula Bladder dysfunction
Body image General improvement with time.
22
consequences Chemoradiation Alopecia Radiation burns
Vaginal stenosis and inflammation Cystitis and colitis Fistula bowel and bladder Side effects tend to get worse with time.
23
The future Improved prevention Less invasive treatment for pre-cancer
vaccination
24
outcome Stage I II III IV 5 year survival 80% 60% 20% 5%
25
Malcolm Padwick MD FRCOG
Gynaecologist West Herts NHS Trust
26
Ovarian Cancer
27
General impression Middle class disease Effects older population
Silent killer One of the diseases GPs fear missing the most Mortality 12 per
28
At risk groups Post menopausal Nulliparous
Family history (including breast cancer) Contraceptive usage Endometriosis Environmental
29
Screening Genetic - BRCA 1 and 2 mutations General population
USS and CA125 ????? Prophylactic oopherectomy after 40 years +/- HRT General population USS and CA125 ????? Research projects only
30
presentation Abdominal distension Abnormal PV bleeding
Abdominal discomfort Dyspepsia Bowel symptoms From physicians and general surgeons
31
Investigations CA125 USS laparoscopy CT MRI
34
Management MDT Surgery +/- chemotherapy
Staging and randomization into interval debulking study Interval debulking Pregnancy associated mass
36
Follow-up CA125 CT Relapse chemotherapy Relapse surgery
37
Outcome Stage I II III IV 5 Year survival 90% 70% 25% 5%
38
Future ?
39
Endometrial Cancer Malcolm Padwick
40
Endometrial Cancer 65 of all cancers in women postmenopausal
obese (hypertensive, diabetic) HRT tamoxifen
41
Symptoms PMB IMB PCB Pap smear Pain
Weight loss, bowel and bladder changes Abnormal bleeding on HRT
42
Managment Refer to the “rapid access clinic” Use cancer pro forma
43
Investigations Pelvic USS
If endometrial signal > 4mm for endometrial biopsy -- either pippelle or hysteroscopy and currettage High risk symptoms go straight to H & C
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.